Last $117.90 USD
Change Today +1.67 / 1.44%
Volume 1.9M
TMO On Other Exchanges
Symbol
Exchange
New York
Stuttgart
Mexico
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TMO) Snapshot

Open
$116.19
Previous Close
$116.23
Day High
$118.49
Day Low
$116.05
52 Week High
03/6/14 - $127.63
52 Week Low
11/8/13 - $95.52
Market Cap
47.1B
Average Volume 10 Days
3.1M
EPS TTM
$3.46
Shares Outstanding
399.4M
EX-Date
09/11/14
P/E TM
34.0x
Dividend
$0.60
Dividend Yield
0.51%
Current Stock Chart for THERMO FISHER SCIENTIFIC INC (TMO)

thermo fisher scientific inc (TMO) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. It operates in three segments: Analytical Technologies; Specialty Diagnostics; and Laboratory Products and Services. The Analytical Technologies segment offers instruments, reagents, consumables, software, and services for a range of applications in the laboratory, on the production line, and in the field. This segment serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The Specialty Diagnostics segment provides various diagnostic test kits, reagents, culture media, instruments, and associated products that are used by customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. This segment offers blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; human leukocyte antigen typing and testing for the organ transplant; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; and products for cancer diagnosis and medical research in histology, cytology, and hematology applications. The Laboratory Products and Services segment offers laboratory equipment, including sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.

50,000 Employees
Last Reported Date: 10/22/14
Founded in 1956

thermo fisher scientific inc (TMO) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $653.7K
Executive Vice President and President of Lab...
Total Annual Compensation: $697.9K
Senior Vice President and President of Analyt...
Total Annual Compensation: $514.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $622.6K
Compensation as of Fiscal Year 2013.

thermo fisher scientific inc (TMO) Key Developments

Thermo Fisher Scientific, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 27, 2014; Revises Earnings Guidance for 2014

Thermo Fisher Scientific, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 27, 2014. For the quarter, the company reported revenues of $4,171.4 million compared to $3,191.8 million a year ago. Operating income was $640.3 million compared to $392.1 million a year ago. Income before income taxes was $539.2 million compared to $319 million a year ago. Net income was $471.6 million or $1.17 per diluted share compared to $317.6 million or $0.86 per diluted share a year ago. Adjusted operating income was $915 million compared to $619.4 million a year ago. Adjusted net income was $690.3 million or $1.71 per share compared to $477 million or $1.30 per share a year ago. Net cash provided by operating activities was $676 million compared to $505.5 million a year ago. Purchases of property, plant and equipment was $90.7 million compared to $56.3 million a year ago. Free cash flow was $593.9 million compared to $463.1 million a year ago. For nine months, the company reported revenues of $12,396.8 million compared to $9,623.4 million a year ago. Operating income was $1,863.9 million compared to $1,154.6 million a year ago. Income from continuing operations before income taxes was $1,550.1 million compared to $941.9 million a year ago. Net income was $1,293.2 million or $3.22 per diluted share compared to $931.2 million or $2.56 per diluted share a year ago. Adjusted operating income was $2,669.1 million compared to $1,858.3 million a year ago. Adjusted net income was $1,996.2 million or $4.97 per share compared to $1,451.4 million or $3.99 per share a year ago. Net cash provided by operating activities was $1,665.9 million compared to $1,282.2 million a year ago. Purchases of property, plant and equipment was $270.9 million compared to $187.9 million a year ago. Free cash flow was $1,418.2 million compared to $1,113.5 million a year ago. The company updating its 2014 revenue guidance primarily to reflect the unfavorable change in foreign currency exchange rates and now expects revenue to be from $16.74 billion to $16.82 billion versus its previous guidance of $16.86 billion to $16.98 billion, for year-over-year growth of 28%. The company is maintaining the midpoint of its adjusted EPS guidance and tightening the range to $6.87 to $6.95 from the $6.85 to $6.97 previously announced, resulting in 27% to 28% adjusted EPS growth over 2013. The 2014 guidance does not include any future acquisitions or divestitures and is based on current foreign exchange rates. In addition, the adjusted EPS estimate excludes amortization expense for acquisition-related intangible assets and certain other items. The company still expecting adjusted income tax rate to be about 15%. The company expecting net interest expense to be in the range of $425 million to $435 million, consistent with previous guidance. The company expecting net capital expenditures to be in the range of $410 million to $430 million, down about $50 million from previous guidance based on actively managing project spend, as well as identifying some duplicate investments as get further into the integration. Finally, in terms of full year 2014 free cash flow, the company maintaining previous guidance of about $2.2 billion.

Thermo Fisher Scientific, Inc. to Report Q3, 2014 Results on Oct 22, 2014

Thermo Fisher Scientific, Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Oct 22, 2014

Thermo Fisher Scientific, Inc., Q3 2014 Earnings Call, Oct 22, 2014

Thermo Fisher Scientific, Inc., Q3 2014 Earnings Call, Oct 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMO:US $117.90 USD +1.67

TMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.46 USD +0.03
Akzo Nobel NV €51.14 EUR -0.47
Danaher Corp $77.96 USD +0.60
General Dynamics Corp $132.50 USD +2.16
Safran SA €48.02 EUR -0.83
View Industry Companies
 

Industry Analysis

TMO

Industry Average

Valuation TMO Industry Range
Price/Earnings 28.4x
Price/Sales 3.0x
Price/Book 2.3x
Price/Cash Flow 22.9x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit www.thermofisher.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.